Mougina K Eltahir

Dr. Mougina K Eltahir

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 July 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MEMougina K Eltahir
Mougina K Eltahir
MNMasayuki Nakamori
Masayuki Nakamori
SHSatoshi Hattori
Satoshi Hattori
TKTakashi Kimura
Takashi Kimura
HMHideki Mochizuki
Hideki Mochizuki
SNSeiichi Nagano
Seiichi Nagano
Myotonic dystrophy type 1 (DM1) is a trinucleotide repeat disorder affecting multiple organs. However, most of the research is focused on studying and treating its muscular symptoms. On the other hand, despite the significant impact of the neurological symptoms on patients’ quality of life, no drug therapy was studied due to insufficient reproducibility in DM1 brain-specific animal models. To establish DM1 neuronal model, human skin fibroblasts were directly converted into neurons by using lentivirus expressing small hairpin RNA (shRNA) against poly-pyrimidine tract binding protein (PTBP). We found faster degeneration in DM1 human induced neurons (DM1 hiNeurons) compared to control human induced neurons (ctrl hiNeurons), represented by lower viability from 10 days post viral-infection (DPI) and abnormal axonal growth at 15 DPI. Nuclear RNA foci were present in most of DM1 hiNeurons at 10 DPI. Furthermore, DM1 hiNeurons modelled aberrant splicing of MBNL1 and 2, MAPT, CSNK1D and MPRIP at 10 DPI. We tested two drugs that were shown to be effective for DM1 in non-neuronal model and found that treatment of DM1 hiNeurons with 100 nM or 200 nM actinomycin D (ACT) for 24 h resulted in more than 50% reduction in the number of RNA foci per nucleus in a dose dependent manner, with 16.5% reduction in the number of nuclei containing RNA foci at 200 nM and treatment with erythromycin at 35 μM or 65 μM for 48 h rescued mis-splicing of MBNL1 exon 5 and MBNL 2 exons 5 and 8 up to 17.5%, 10% and 8.5%, respectively. Moreover, erythromycin rescued the aberrant splicing of MAPT exon 2, CSNK1D exon 9 and MPRIP exon 9 to a maximum of 46.4%, 30.7% and 19.9%, respectively. These results prove that our model is a promising tool for detailed pathogenetic examination and novel drug screening for the nervous system.

Verified
Journal Article
Open access
PDF file
LALoulwah Alothman
Loulwah Alothman
AAAlaa Alnoor Alnoor Alameen
Alaa Alnoor Alnoor Alameen
MEMougina K Eltahir
Mougina K Eltahir
Oral lichen planus (LP) is widely described as molecularly distinct from cutaneous LP, yet most supporting transcriptomic evidence compares mucosal epithelium with full-thickness skin. We reanalysed four public microarray series covering oral, genital and cutaneous LP (101 arrays) with matched microRNA arrays, using covariate-adjusted models, meta-analysis, cross-platform integration, a within-platform site-by-disease interaction model, pathway and deconvolution scoring and a test of experimentally supported microRNA–target interactions. Eighty-five genes were differentially expressed at both discovery sites, 83 concordantly, dominated by cornified-envelope and keratinisation genes; BPIFC, CDSN and WFDC12 replicated in all four cohorts. A 52-gene barrier score separated lesional from control tissue in the discovery and genital cohorts (AUC 0.98–1.00, partly in-sample), and panels derived at one LP site transferred across study, platform and site (AUC 0.95–0.99), but the score did not reach significance in the only fully independent oral cohort (AUC 0.76, p = 0.13). In comparator series, the programme was also induced in psoriasis and partly in cutaneous lupus, but not in atopic dermatitis, eosinophilic oesophagitis or periodontitis, so it is shared rather than LP-specific. Interferon and MYC-target activity and several immune populations were higher in cutaneous LP, but an epithelial:immune compartment proxy showed that cutaneous biopsies were full-thickness whereas mucosal biopsies were epithelium-only, confounding this contrast. Within one platform, 292 genes showed an oral-versus-genital interaction. Neither miR-20a-5p nor miR-34a-5p tracked barrier expression, and across 222,203 supported microRNA–target pair correlations were predominantly positive rather than inverse. Across LP sites, a reproducible epithelial barrier programme is the most consistent shared feature, although it is not specific to LP and its transfer to independent cohorts remains provisional; reported immune divergence cannot be separated from the biopsy compartment.

13 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LALoulwah Alothman
Loulwah Alothman
AAAlaa Alnoor Alnoor Alameen
Alaa Alnoor Alnoor Alameen
MAMohammed M Alshehri
Mohammed M Alshehri
AAAbdullah Mohamed Abdullah
Abdullah Mohamed Abdullah
HAHala Aldahshan
Hala Aldahshan
MEMougina K Eltahir
Mougina K Eltahir
Background/Objectives: Myocardial infarction (MI) remains a major therapeutic challenge, and the molecular targets potentially associated with the cardiovascular activity of Adansonia digitata phytochemicals remain incompletely characterized. This study integrated phytochemical, transcriptomic, disease-gene, network, and structural evidence to prioritize candidate phytochemical–MI target associations. Methods: Ten polyphenols were selected from published LC-MS/QTOF data. Targets predicted using SwissTargetPrediction and PharmMapper were integrated with MI-associated evidence from the GSE66360 (circulating endothelial cell), GSE325257 (cardiac targeted gene-expression), and DisGeNET. An initial composite analysis generated a 19-gene discovery module for network and structural prioritization. A complementary source-resolved sensitivity analysis independently evaluated the three MI evidence sources. Selected interactions were examined by molecular docking, 200 ns molecular dynamics simulations, and MM/PBSA binding free-energy estimation. Results: Sensitivity analysis identified 189 genes supported by at least two MI evidence sources, including 21 predicted Adansonia digitata targets. Four genes (GSK3B, NOS3, SOD2, and TGFBR1) were shared between the 19-gene discovery and 21-gene sensitivity modules. Gene Ontology analysis identified 36 significantly overrepresented biological-process terms (FDR < 0.05). Docking supported the selection of chlorogenic acid and rutin for simulation with MMP2 and NOS3. MM/PBSA calculations indicated that chlorogenic acid exhibited more favorable estimated binding energies compared to rutin, especially in the case of MMP2. However, these differences were not statistically validated. Conclusions: The complementary integration strategies prioritized candidate Adansonia digitata phytochemicals and MI-associated targets and generated testable hypotheses for further investigation. These computational findings are hypothesis-generating and require experimental validation of target engagement, biological activity, pharmacokinetics, and efficacy in MI models.